

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2023

Reference is made to the annual report of Aceso Life Science Group Limited (the “**Company**”) for the year ended 31 March 2023 published on 26 July 2023 (the “**Annual Report**”). Unless otherwise defined in this announcement or the context requires, capitalised terms used herein shall have the same meanings as those defined in the Annual Report.

In addition to the information provided in the Annual Report, the board of directors of the Company (the “**Board**”) would like to provide additional information regarding the disclosure with respect to the Group as below:

(A) THE TOTAL NUMBER OF SHARE OPTIONS OF THE COMPANY AVAILABLE FOR GRANT FOR THE YEAR ENDED 31 MARCH 2023

The total number of shares available for grant under the share option scheme was 328,430,310 Shares and 328,430,310 Shares as at 1 April 2022 and 31 March 2023, respectively. At 31 March 2023, the total number of shares available for grant represents 4.45% of the issued shares of the Company.

(B) MOVEMENTS OF SHARE OPTIONS OF THE COMPANY FOR THE YEAR ENDED 31 MARCH 2023

During the year ended 31 March 2023, there was no share options granted, exercised, lapsed or cancelled. The percentage to issued shares of the Company at the date of the Annual Report was nil.

(C) MOVEMENTS OF SHARE AWARDS OF THE COMPANY FOR THE YEAR ENDED 31 MARCH 2023

During the year ended 31 March 2023, there was no award Shares granted, vested, issued, lapsed or cancelled. The percentage to weighted average number of the issued shares of the Company was nil.

The total number of awards available for grant (subject to the listing approval) under the share award scheme as at 1 April 2022 and 31 March 2023 were 44,253,262 Shares and 44,202,862 Shares, respectively.

At the date of the Annual Report, the total number of shares available for issue ((i) the total number of awards available for grant under the share award scheme and (ii) the outstanding and unvested shares) was 44,202,862 Shares, which represents 0.59% of the issued shares of the Company.

The aggregate value of the shares which may be issued to any individual at any one time shall not exceed HK\$5 million as at the date of share award granted under the share award scheme.

SHARE SCHEMES ADOPTED BY HTICI

HTICI, the non-wholly owned subsidiary of the Company and whose shares are listed on the Stock Exchange (stock code: 1341), has adopted a share option scheme and a share award scheme on 23 October 2015 and 24 April 2020 respectively.

For the share option scheme, subject to the restrictions under the Listing Rules, options may be exercised at any time from the date which options is deemed to be granted and accepted and expired on the date as the Board in its absolute discretion determine and which shall not exceeding a period of 10 years from the date on which the share options are accepted but subject to the previous for early termination thereof contained in the share option scheme.

The details of the schemes adopted by HTICI were as below:

(a) THE TOTAL NUMBER OF SHARE OPTIONS OF HTICI AVAILABLE FOR GRANT FOR THE YEAR ENDED 31 MARCH 2023

The total number of shares available for grant under the share option scheme of HTICI was 100,000,000 shares and 100,000,000 shares as at 1 April 2022 and 31 March 2023, respectively. At 31 March 2023, the total number of shares available for grant represents 1.32% of the issued shares of HTICI.

(b) MOVEMENTS OF SHARE OPTIONS OF HTICI FOR THE YEAR ENDED 31 MARCH 2023

During the year ended 31 March 2023, there was no share options granted, exercised, lapsed or cancelled. The percentage to issued shares of HTICI at the date of the Annual Report was nil.

(c) SHARE AWARD SCHEME OF HTICI

HTICI has adopted the share award scheme on 24 April 2020, being an incentive measure to recognise the contributions by selected participants and to provide them with incentives in order to retain them; and to attract the right talents for promoting the future development and expansion of group of companies held by HTICI (the “**HTICI Group**”), with a view to achieving the objective of increasing the value of the HTICI Group by motivating the participants to strive for the continual operation and future development and expansion of the HTICI Group and aligning the interests of the participants and the shareholders of HTICI. Subject to the restrictions under the Listing Rules, participants include any director (including executive director, non-executive director and independent non-executive director), employee (whether full time or part time), officer, agent or consultant of HTICI or any of its subsidiaries or any of its affiliates or any other person as determined by the board of directors of HTICI, whom the board of directors of HTICI considers, in its absolute discretion, has contributed or will contribute to the HTICI Group. Unless early terminated by the board of directors of HTICI, the share award scheme of HTICI shall be valid and effective for a term of 10 years commencing on the adoption date (i.e. 24 April 2020) and will expire on 23 April 2030. The board of directors of HTICI has resolved to grant (i) a total of 196,274,929 award shares of HTICI to selected grantees who are not connected with HTICI on 24 April 2020; and (ii) a total of 65,475,610 award shares of HTICI to selected grantees who are connected with HTICI on 29 June 2020. The award shares of HTICI granted under the scheme are subject to a vesting scale in three equal tranches. The remaining life of the share award scheme is 7 years.

(d) MOVEMENTS OF SHARE AWARDS OF HTICI FOR THE YEAR ENDED 31 MARCH 2023

The movements of share awards during the year ended 31 March 2023 were as follows:

Name/ category of grantees	Date of grant	Vesting period	Number of share awards granted under the share award scheme	Changes in the number of the award shares during the year							% to weighted average number of issued shares of HTICI in the year	Consideration HK\$
				Outstanding and unvested as at 1 April 2022	Granted during the year	Vested during the year	Issued during the year	Lapsed during the year	Cancelled during the year	Outstanding and unvested as at 31 March 2023		
Director of the Company/its subsidiary												
Fok Chi Tak	29/6/2020	29 June 2020 to 29 June 2023	60,975,610	40,650,407	-	20,325,203	20,325,203	-	-	20,325,204	0.27%	Nil
Lai Chi Hang	29/6/2020	29 June 2020 to 29 June 2023	1,500,000	1,000,000	-	500,000	500,000	-	-	500,000	0.01%	Nil
Cheung Wang Lok	29/6/2020	29 June 2020 to 29 June 2023	1,500,000	1,000,000	-	500,000	500,000	-	-	500,000	0.01%	Nil
Leung Ka Kit	29/6/2020	29 June 2020 to 29 June 2023	1,500,000	-	-	-	-	-	-	-	-	Nil
Sub-total			65,475,610	42,650,407	-	21,325,203	21,325,203	-	-	21,325,204	0.29%	Nil
Other Employees	24/4/2020	24 April 2020 to 24 April 2023	196,274,929	17,000,002	-	8,500,000	8,500,000	2,000,001	-	6,500,001	0.09%	Nil
			261,750,539	59,650,409	-	29,825,203	29,825,203	2,000,001	-	27,825,205	0.38%	Nil

During the year ended 31 March 2023, a total of 8,500,000 shares have been issued to the grantees who are not connected with HTICI in April 2022 at nil consideration and a total of 21,325,203 shares have been issued to the grantees who are connected with HTICI in June 2022 at nil consideration. The weighted average closing price of the shares of HTICI immediately before the dates on which the award Shares were vested was HK\$0.394.

There was no purchase price of the unvested award Shares as at 1 April 2022 and 31 March 2023.

The total number of awards of HTICI available for grant (which is subject to the listing approval) under the share award scheme were 494,185,070 shares (which represents 6.54% of the issued shares of HTICI) and 497,444,013 shares (which represents 6.55% of the issued shares of HTICI) as at 1 April 2022 and 31 March 2023, respectively.

At the date of the Annual Report, the total number of shares available for issue ((i) the total number of awards available for grant under the share award scheme and (ii) the outstanding and unvested shares) was 525,269,218 shares, which represents 6.92% of the issued shares of HTICI.

There was no maximum entitlement of each participant under the share award scheme of HTICI.

The supplemental information stated in this announcement does not affect other information contained in the Annual Report. Save as disclosed above, all other information in the Annual Report remains unchanged.

By order of the Board
Aceso Life Science Group Limited
Fok Chi Tak
Executive Director

Hong Kong, 29 February 2024

As at the date of this announcement, the Board comprises two executive Directors, namely Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; and three independent non-executive Directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.